Cyprium Therapeutics, Inc. Cyprium, a Fortress Biotech company, is focused on the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders. CUTX-101 is under investigation for the treatment of Menkes disease and related copper metabolism disorders. It...
Fortress Biotech (NASDAQ:FBIO) partner Cyprium Therapeutics has received a positive opinion from the European Medicines Agency (EMA) for its application for...
【异动股】Alterity Therapeutics (ASX:ATH)帕金森症修饰候选药物2期临试顺利收官 澳洲生物科技公司Alterity Therapeutics Ltd (ASX股票代码:ATH)宣布完成帕金森症疾病修饰候选药物ATH434-201第2阶段试验最后一名患者的临床评估,预计将在2025年1月底或2月初报告顶线结果。 周四截止澳东时间下午12.10,ATH澳交所股价应声飙...
【异动股】Alterity Therapeutics (ASX:ATH)帕金森症修饰候选药物2期临试顺利收官 澳洲生物科技公司Alterity Therapeutics Ltd (ASX股票代码:ATH)宣布完成帕金森症疾病修饰候选药物ATH434-201第2阶段试验最后一名患者的临床评估,预计将在2025年1月底或2月初报告顶线结果。 周四截止澳东时间下午12.10,ATH澳交所股价应声飙...